WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (Tevogen or Tevogen Bio Holdings Inc.) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech creating off-the-shelf, genetically unmodified T cell therapeutics to deal with infectious illness and cancers.
Since being based in 2020, Tevogen Bio has taken a singular method to each drug improvement and managing its enterprise operations. The corporate launched is proprietary ExacTcell™ know-how, designed to create accessible and disease-specific mobile immunotherapies. Tevogen Bio acquired 3 U.S. patents, with a further 9 patents pending, together with 2 for Synthetic Intelligence, and has filed 12 worldwide functions. Moreover, the corporate reported constructive proof-of-concept scientific trial knowledge for the primary scientific product of its proprietary know-how.
As of the quarter ending June 30, 2024, officers of Tevogen Bio held almost 79% of the corporate’s excellent shares. Any reported gross sales by officers have been made solely to fulfill the cost of tax obligations regarding the vesting of restricted inventory items and weren’t made on the discretion of the reporting officer. Tevogen CEO and founder, Dr. Saadi, MD, MPH, emphasised his dedication to the corporate’s mission of bringing accessible therapeutics to market. He famous, The management staff’s retention of 100% of their fairness displays their confidence within the firm’s potential. With over half a billion shares traded on the open market this week, I wish to categorical my gratitude for this unprecedented public help for Tevogen’s enterprise mannequin. Dr. Saadi added, I used to be happy that Tevogen was in a position to present updates on the corporate, together with, our pipeline, our oncology forecast of $1 billion in launch yr, and I count on to proceed sharing particulars about further progress within the coming days.
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy firm harnessing certainly one of nature’s strongest immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the remedy of infectious illnesses, cancers, and neurological problems, aiming to deal with the numerous unmet wants of huge affected person populations. Tevogen Leadership believes that sustainability and industrial success within the present period of healthcare depend on guaranteeing affected person accessibility via superior science and revolutionary enterprise fashions. Tevogen has reported constructive security knowledge from its proof-of-concept scientific trial, and its key mental property belongings are wholly owned by the corporate, not topic to any third-party licensing agreements. These belongings embody three granted patents, 9 pending US and twelve ex-US pending patents, two of that are associated to synthetic intelligence.
Tevogen is pushed by a staff of extremely skilled trade leaders and distinguished scientists with drug improvement and world product launch expertise. Tevogen’s management believes that accessible personalised therapeutics are the subsequent frontier of medication, and that disruptive enterprise fashions are required to maintain medical innovation.
Ahead Trying Statements
This press launch comprises sure forward-looking statements, together with with out limitation statements regarding: expectations concerning the healthcare and biopharmaceutical industries; Tevogen’s improvement of, the potential advantages of, and affected person entry to its product candidates for the remedy of infectious illnesses, most cancers and neurological problems, together with TVGN 489 for the remedy of COVID-19 and Lengthy COVID; Tevogen’s capability to develop further product candidates, together with via use of Tevogen’s ExacTcell platform; the anticipated advantages of ExacTcell; expectations concerning Tevogen’s future scientific trials; and Tevogen’s capability to generate income sooner or later. Ahead-looking statements can typically be recognized by phrases similar to could, might, would, count on, anticipate, potential, potential, aim, alternative, venture, consider, future, and comparable phrases and expressions or their opposites. These statements are primarily based on administration’s expectations, assumptions, estimates, projections and beliefs as of the date of this press launch and are topic to a lot of elements that contain identified and unknown dangers, delays, uncertainties and different elements not beneath the corporate’s management that will trigger precise outcomes, efficiency or achievements of the corporate to be materially completely different from the outcomes, efficiency or different expectations expressed or implied by these forward-looking statements.
Elements that would trigger precise outcomes, efficiency, or achievements to vary from these expressed or implied by forward-looking statements embody, however are usually not restricted to: that Tevogen might want to increase further capital to execute its marketing strategy, which will not be obtainable on acceptable phrases or in any respect; the impact of the current enterprise mixture with Semper Paratus Acquisition Company (the Business Mixture) on Tevogen’s enterprise relationships, working outcomes, and enterprise usually; the result of any authorized proceedings that could be instituted in opposition to Tevogen; modifications within the markets by which Tevogen competes, together with with respect to its aggressive panorama, know-how evolution, or regulatory modifications; modifications in home and world basic financial situations; the chance that Tevogen could not be capable to execute its progress methods or could expertise difficulties in managing its progress and increasing operations; the chance that Tevogen could not be capable to develop and preserve efficient inner controls; prices associated to the Business Mixture and the failure to comprehend anticipated advantages of the Business Mixture; the failure to attain Tevogen’s commercialization and improvement plans and establish and understand further alternatives, which can be affected by, amongst different issues, competitors, the power of Tevogen to develop and handle progress economically and rent and retain key workers; the chance that Tevogen could fail to maintain tempo with speedy technological developments to offer new and revolutionary services and products or make substantial investments in unsuccessful new services and products; the power to develop, license or purchase new therapeutics; that Tevogen might want to increase further capital to execute its marketing strategy, which will not be obtainable on acceptable phrases or in any respect; the chance of regulatory lawsuits or proceedings regarding Tevogen’s enterprise; uncertainties inherent within the execution, price, and completion of preclinical research and scientific trials; dangers associated to regulatory evaluation, approval and industrial improvement; dangers related to mental property safety; Tevogen’s restricted working historical past; and people elements mentioned or included by reference in Tevogen’s Annual Report on Type 10-Okay and subsequent filings with the SEC.
You shouldn’t place undue reliance on forward-looking statements, which converse solely as of the date they’re made. Tevogen undertakes no obligation to replace any forward-looking statements, besides as required by relevant legislation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Supply: Tevogen Bio Inc
